The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...

Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

In April 2025, we published a story with the headline: "Haunted by hopelessness: 12 Zambians share their stories as HIV drugs run out." It looked at the impact of President Trump's cuts to foreign aid ...

The city's axess sexual health service is piloting a new online platform that will deliver preventative HIV medication PrEP direct to patients without the need for them to have an in-person ...

A new project co-led by Brown researchers is looking to tackle the recent rise in substance abuse, HIV, hepatitis C and ...